A Th1 inducing adjuvant, MPL®, safely assists in reducing the length of a pollen allergy vaccination course

Alergologia e Inmunologia Clinica

Volumn 17, Issue 1, 2002, Pages 39-43

  Drachenberg, K J ^a   Wheeler, A W ^a   Woroniecki, S R ^a   Horak, F ^a  

^a Allergy Therapeutics Ltd   (United Kingdom)

Author keywords

Allergy vaccine; Grass pollen; Monophosphoryl lipid A; MPL ; Th1

Indexed keywords

3 DEACYL PHOSPHORYL LIPID A; GRASS POLLEN EXTRACT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; MPL; PHOSPHORYL LIPID A; PLACEBO; POLLINEX; UNCLASSIFIED DRUG; VACCINE;

ANTIBODY TITER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POLLEN ALLERGY; REVIEW; SYMPTOMATOLOGY; TH1 CELL; VACCINATION;

EID: 0036117869     PISSN: 1575734X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (9)

1. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper
2. Economic Evaluation of Specific Immunotherapy versus Symptomatic Treatment of Allergic Rhinitis in Germany
3. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions
4. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines
5. Induction of cell-mediated immune responses in man with vaccines against Herpes simplex virus based on glycoprotein D
6. Monophosphoryl lipid A ((MPL) has Th1 stimulating properties in immunotherapy with birch pollen allergoid
7. Novel adjuvants in clinical testing November 2-4, 1998, Fondation Mérieux, Annecy, France: A meeting sponsored by the World Health Organization